NR1I2 and breast cancer: Indeed, PXR activation has been shown to have an anti-apoptotic role in colon cancer cells [25] and induces FGF19-dependent tumor aggressiveness in humans and mice [26], whereas PXR antagonist decreased cell proliferation in breast cancer [27] and interfered with cancer drug resistance [28].